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Abstract: Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical 
and preclinical studies investigated the possible relationship between host metabolism and BC. 
Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can 
promote tumorigenesis through a direct effect on epithelial tissues or indirectly by affecting the 
levels of other modulators, such as the insulin-like growth factor (IGF) family of receptors, sex 
hormones, and adipokines. The potential anti-cancer activity of metformin is based on two principal 
effects: first, its capacity for lowering circulating insulin levels with indirect endocrine effects that 
may impact on tumor cell proliferation; second, its direct influence on many pro-cancer signaling 
pathways that are key drivers of BC aggressiveness. Methods: In the present review, the interaction 
between BC, host metabolism, and patients’ prognosis has been reviewed across available literature 
evidence. Conclusions: Obesity, metabolic syndrome, and insulin resistance are all involved in BC 
growth and could have a relevant impact on prognosis. All these factors act through a pro-
inflammatory state, mediated by cytokines originated in fat tissue, and seem to be related to a higher 
risk of BC development and worse prognosis. 
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1. Introduction 
In Western Countries, a large proportion of diseases, including cancer, can be 
attributed to a Western lifestyle, in association with physical inactivity and metabolic 
impairment. A growing body of evidence suggests a strong relationship among type 2 
diabetes mellitus (T2DM), insulin, obesity, and cancer. The association between insulin 
and cancer is based on the strong anabolic effect of hyperinsulinemia that leads to 
proliferative tissue abnormalities, stimulation of DNA synthesis, and cell proliferation [1]. 
Preclinical studies demonstrated that insulin can promote tumorigenesis through a 
direct effect on epithelial tissues or indirectly by affecting the levels of other modulators, 
such as the insulin-like growth factor (IGF) family of receptors, sex hormones, and 
adipokines [2]. IGFs are endocrine mediators of growth hormones that act in a paracrine 
and autocrine fashion to regulate cell growth, differentiation, apoptosis, and 
transformation in different tissues, including breast tissue. Insulin receptors (IR) regulate 
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glucose, protein, and lipid metabolism through the phosphatidylinositol 3-kinase 
(PI3K)/AKT pathway and through the activation of the RAS/RAF/MAPK kinase/ERK 
cascade that is involved in cell proliferation, survival, and migration [3]. 
Breast cancer (BC) is the most common cancer in women, with over 2 million of new 
diagnosis/year in 2018 in the world [4]. In the last years, the possible interactive role of 
host metabolism and BC has risen in importance, and many clinical and preclinical studies 
have been developed to understand their possible correlations. In particular, obesity has 
been consistently reported as a risk factor for different BC subtypes, including triple 
negative (TNBC) and luminal BC [5,6]. Available evidence also shows that BC cells have 
significantly higher insulin receptor (IR) levels than normal breast cells [7], suggesting 
that this signaling pathway may play a role in BC development and progression, and may 
become a potential therapeutic target. Furthermore, epidemiologic studies have shown 
that high levels of plasmatic IGF are correlated with an increased risk of several cancers, 
including breast, and that IGF-2 signaling is possibly associated with cancer progression 
[8]; it is also known that the loss of tumor suppressor genes such as BRCA1, p53, and 
PTEN leads to an increase in IGF-1R expression in tumors [9]. 
In this preclinical context, E-cadherin is a putative regulator of IGF1 signaling; the 
loss of E-cadherin expression can directly increase IGF1-R pathway activation in many 
BCs. The oncogenic signaling network may be influenced by the regulation of IGF1-R by 
E-cadherin, particularly because E-cadherin itself is involved in mechanisms of escape of 
tumor cells and metastasization. In addition, the transcription of E-cadherin is repressed 
or genetically lost in subset of breast tumors, such as invasive lobular breast carcinoma 
(ILC), in which its loss of functional occurs in about 95%. Due to the loss of E-cadherin 
protein, ILC cells grow in linear patterns throughout the breast tissue, lacking the ability 
to form adhesion junctions, in contrast to the solid mass growth of the most frequent 
subtype of breast cancer, invasive ductal breast carcinoma (IDC) [10,11]. 
In BC patients, the possible role of the IGF pathway in resistance to cancer therapy 
has been investigated, although the exact mechanism is not completely clear. In particular, 
the IGF pathway seems to be involved in modulating the expression of Epidermal Growth 
Factor receptors (EGFR) in cancer cells, and, as a consequence, it might have a key role in 
inducing resistance to endocrine therapies in estrogen receptor (ER)-positive BC patients 
[12,13]; in addition, direct interactions between the IGF-1R and the HER2 pathway have 
been reported and may contribute to the resistance to anti-HER2–targeted therapy [14] 
(Table 1). 
Table 1. Insulin-like growth factor (IGF) expression (%) according to breast cancer (BC) patients’ 
characteristics: A higher expression is observed in patients with worse prognostic features. 
BC Characteristics IGF Expression (%) 
Histological subtype  
ER+ 60 
TNBC 20 
Tumor staging  
T1-T2 35 
T3-T4 65 
Lymph nodes metastasis  
Yes 60 
No 40 
ER: Estrogen receptor; TNBC: Triple-negative breast cancer. Adapted from [15,16]. 
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2. Host Metabolism and Breast Cancer Risk 
The possible relationship between cancer and obesity is very complex: Body mass 
index (BMI), an easy and immediate biometric index, deriving from weight and height 
and routinely used in clinical practice, cannot be considered an exact index of metabolic 
health, as obese patients can be metabolically healthy and normal-weight patients can be 
un-healthy. Moreover, its role as a risk factor for BC is dual: recent evidence has shown 
that increased adiposity in childhood and in early adulthood is associated with a reduced 
risk of BC, whereas increased adiposity after menopause is associated with an increased 
BC risk [17]. A large pooled analysis on about 750,000 premenopausal women 
demonstrated a higher risk of BC in those who were underweight as compared to those 
obese, showing an inverse association between BMI and BC risk, suggesting a critical 
correlation between young adulthood adiposity and cancer; this association seems to be 
independent from other well-known BC risk factors. The association between BMI and 
hormone receptor positive BC is stronger in young adulthood, but not consistent in later 
ages, while the correlation between obesity and TNBC is more controversial. 
The association between estrogen receptor-positive (ER+) BC and obesity identifies a 
possible hormonal role in tumorigenesis, as the adipose tissue is the principal site of 
estrogen release in childhood; for this reason, overweight in childhood seems to induce 
early breast differentiation and to increase expression of tumor suppression gene [18]. 
The relationship between BC subgroups and obesity has been investigated in an 
Italian trial on 2148 women. Overweight/obese women had significantly larger tumors at 
diagnosis than under/normal weight women, both in pre-menopause and post-
menopause. Postmenopausal women with BMI > 25 had a significantly higher percentage 
of hormone positive tumors than lean women, probably because insulin itself stimulates 
ovarian synthesis of androgens, induces expression of growth hormone (GH) receptors, 
decreases liver production of sex hormone binding globulin (SHBG) and two IGF-binding 
proteins (IGFBP-1 and -2), increasing the bio-availability of sexual hormones and IGF-1 
[19]. 
In postmenopausal women, the presence of metabolic disorders and obesity has been 
consistently identified as a strong risk factor for BC [20], possibly due to the underlying 
chronic inflammation at the level of peripheral tissues [21]; furthermore, 
hyperinsulinemia itself was found to be an independent risk factor for post-menopausal 
BC [22]. In particular, the most striking evidence is reported in the Nurses’ Health Study, 
which included 5204 women diagnosed with BC between 1976 and 2000. In this study, 
women experiencing a gain in BMI during the observation period, ranging from 0.5 to 2 
kg/m2 or >2 kg/m2 had a relative risk of BC increased by 1.35 and 1.64 times, respectively 
[23]. 
Association between obesity and BC seems also to be modulated by fat distribution: 
in post-menopausal patients, an increased fat mass of the trunk is related with a higher 
risk of BC [21,24]. Indeed, post-menopausal women tend to experience a re-distribution 
of body fat from a gynoid to an android pattern, which is supposed to be more 
metabolically important than general obesity and is also linked to the occurrence of the 
metabolic syndrome and cardiovascular disease [25]. 
An immunohistochemical analysis of levels of IGFR-1 was performed in a group of 
144 females with TNBC to evaluate a possible correlation with their prognosis. 
Immunohistochemistry was performed on paraffin-embedded tumor tissues: An increase 
in IGFR-1 expression (99%) was detected in the majority of cases (63%), associated with 
reduced overall survival (OS) and disease free survival (DFS) [26]. 
While the relationship between BMI and ER + BC is well established, available 
evidence about the possible association between TNBC and BMI is less clear [27,28]. 
A pooled analysis on the Breast Cancer Association Consortium revealed that among 
women <50 years of age, obesity was associated more frequently with hormone negative 
BC than with hormone positive tumors and, by including human epidermal growth factor 
receptor 2 (HER2) receptors, obesity was confined to TNBC [29]. 
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3. Host Metabolism and Breast Cancer Prognosis 
The association between BMI and BC prognosis is supported by several observations 
[30]. Obesity represents a well-known pro-inflammatory state, resulting in increased 
levels of inflammatory cytokines such as TNFα and IL-6 [31]. TNF-α is a well-documented 
pro-inflammatory cytokine that is up-regulated in BC and associated with BC recurrence. 
Similarly, high circulating IL-6 levels are correlated with a poor prognosis in BC patients 
[32]. Indeed, elevated systemic levels of this cytokine are a biomarker of tumor burden 
and could be found in cases of impaired metabolism and physical inactivity [33]. 
The possible role of insulin resistance has been evaluated in a trial including 55 
female patients with operable stage III BC. Thirteen (54.5%) patients had insulin resistance 
associated with a higher BMI, triglyceride, and fasting glucose level compared to patients 
without insulin resistance. As a result of this study, the probability of having a 
pathological complete response (pCR) after neo-adjuvant therapy in patients with insulin 
resistance was lower compared to those without insulin resistance, suggesting a possible 
negative effect of insulin resistance on pCR following neoadjuvant therapy, particularly 
with hormone-positive and Her-2 negative cases of non-diabetic BC [34]. 
Recently, the role of BMI on BC prognosis has been evaluated in 1066 women with 
high-risk early BC enrolled in a phase III trial of adjuvant chemotherapy (IBIS). In this 
specific population, there was no evidence of a detrimental effect of increased BMI, 
suggesting that in the presence of aggressive biological subtypes, host factors might have 
a minor effect on patients’ prognosis [35]. 
Epidemiologic evidences suggest that obesity worsens BC prognosis due to the 
increase of recurrence, metastasis, and mortality. As previously mentioned, in overweight 
or obese patients, BCs tend to be bigger at the diagnosis, with positive lymph-nodes, and 
higher tumor burden and grade [36]. 
In advanced BC disease, obesity is also related to a worse impact in response to 
chemotherapy, which dosage could often be reduced to avoid toxicities; furthermore, 
obesity increases risks of every treatment complication and is associated to an incidence 
of metastatic BC disease regardless of tumor subtype [37]. 
A systematic literature review and meta-analysis of follow-up studies by Chan et al. 
clearly supports that, in breast cancer survivors, higher BMI is consistently associated 
with lower OS. This increased risk is similar in pre- or post-menopausal BC: furthermore, 
obesity has a protective effect in pre-menopausal women on the development of BC, 
whereas it has no protective effect on survival after pre- menopausal BC. Compared with 
normal weight women, significant or borderline significant increased risks of BC 
mortality were only observed for morbidly obese (≥40 kg/m2) women and not for women 
in other obesity categories [38]. 
The relationship between BMI in BC growth seems to be mediated by 
hyperinsulinemia. There is evidence that metabolic changes associated with insulin 
resistance are involved in tumor development and aggressiveness. Diabetes has also been 
associated with a more aggressive cancer phenotype and a poorer response to treatment, 
worsening its prognosis [39]. 
In literature data, obesity tends to be associated with a risk reduction of BC among 
pre-menopausal women, that may be attributed to lower levels of serum estradiol and 
progesterone. Conversely, obesity is associated with an increased risk of BC in 
postmenopausal women, related to higher levels of circulating bioavailable estrogen [40]. 
To explore the association between BC and risk and prognostic factors related to 
body size, the CASH study (cancer and steroid hormones) has been conducted on 3924 
women: in this cohort, adult BMI was significantly associated with BC mortality, in 
accordance with a growing body of evidence suggesting that obesity could be an 
independent and preventing risk and prognostic factor in BC [41]. 
Insulin resistance has been shown to be associated with the luminal B BC subtype in 
a cohort of 760 post-menopausal patients. The multivariate analyses showed that an 
Homeostatic model assessment index (HOMA-I) ≥2.0 was significantly correlated with 
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luminal B/HER-2-negative subtype. Moreover, Ki-67 was higher in insulin resistant 
patients [42]. 
Potential association with obesity, metabolic syndrome, and insulin resistance was 
deeply investigated also for TNBC. The IGF-1 receptor is expressed also on the surface of 
TNBC cells; its signal transduction can increase cell proliferation and promote cell 
survival in vitro in several TNBC cell lines. Conversely, decreased IGF-1 receptor 
expression seems to reduce cellular proliferation [43]. 
A pooled analysis revealed that association between obesity and metabolic syndrome 
is more frequently observed in TNBC vs. ER+/HER2 tumors, particularly in younger 
women (age <50)[29]. Moreover, women with triple-negative tumors seem to have a high 
prevalence of metabolic syndrome, characterized by increased BMI and circulating levels 
of insulin and related growth factors, leading to uncontrolled cell proliferation [44] and 
worse prognosis. Several other studies were conducted to investigate the potential role of 
obesity in TNBC development, with controversial results [45]. 
In conclusion, obesity, metabolic syndrome, and insulin resistance are mutually 
involved in BC prognosis. All these factors seem to act through a pro-inflammatory state, 
mediated by cytokines originating in the adipose tissue. In particular, android fat pattern 
is related to a higher risk of BC and a worse prognosis. 
4. The Role of Metformin 
Metformin is an oral biguanide that inhibits hepatic gluconeogenesis and sensitizes 
insulin action at the peripheral level, and it is one of the drugs of choice for the 
management of T2DM [46]. It inhibits hepatic glucose production through an 
LKB1/AMPK-mediated mechanism; it also improves insulin sensitivity in peripheral 
tissues and reduces the incidence of diabetes in persons at high risk, with beneficial effects 
persisting for at least 10 years [47]. It has a good safety profile and an extremely low cost, 
thus being easily accessible in clinical practice. 
It has already been discussed that hyperinsulinemia increases cancer risk in healthy 
subjects and can partly explain the obesity–cancer risk association. In this perspective, in 
the past years, metformin has been extensively studied as a possible anticancer agent. In 
fact, due to its mechanism of action, metformin might interfere with carcinogenesis 
through direct and indirect mechanisms (Figures 1 and 2). 
 
Figure 1. The pathway that corroborates the hypothesis of the direct effect of metformin on tumor 
cell proliferation. 
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Figure 2. The pathway involved in the indirect effect of metformin in inhibition of cancel cell 
proliferation through the reduction of insulin/IGF1 axis. 
Many preclinical studies have shown that metformin has a direct antiproliferative 
effect on cancer cells in vitro and in vivo; in particular, this effect seems to be related to 
the interference with the AMPK pathway, a central cellular key energy sensor allowing 
cell division, and an integrator of different regulatory inputs implicated in cell growth 
[48]. Evidence from epidemiological studies indicate that overweight/insulin resistant 
women seem to benefit more from the use of metformin in terms of BC incidence as 
compared to other antidiabetic drugs; these results could be related to the indirect anti-
cancer effect of metformin through the reduction of systemic insulin levels and 
hyperglycemia [49]. 
In conclusion, the potential anti-cancer activity of metformin is based on two 
principal aspects: first, its capacity for lowering circulating insulin levels with indirect 
endocrine effects that may impact tumor cell proliferation; second, its direct influence on 
the many pro-cancer signaling pathways regulated by PI3K/AKT/mTOR, which are key 
drivers of BC aggressiveness. 
On the basis of these observations, many clinical trials are evaluating the possible 
role of metformin in BC prevention and care [50]. In the past few years, epidemiologic 
studies reported discordant results, with a reduction in cancer incidence and mortality in 
some and no effect in other observations. A meta-analysis of Gandini et al. found that 
metformin administration was significantly associated with decreased BC incidence after 
adjustment for time-related biases, even though the magnitude of this effect was rather 
small [49]. 
The possible anticancer effects of metformin have also been prospectively 
investigated in a different setting of BC care. 
A recent clinical trial showed that metformin acts on BC tumor cell proliferation 
differently, with a positive trend toward inhibiting proliferation only in women with 
insulin resistance or higher BMI [51]. 
In a large observational study of patients with early BC treated with pre-operative 
chemotherapy, the rate of pathological complete responses was significantly higher in 
diabetic patients treated with metformin, as compared to diabetic patients treated with 
other antidiabetic drugs and to non-diabetic BC patients [52]. In the adjuvant setting, a 
large trial on non-diabetic women with early BC comparing metformin with matching 
placebo in terms of disease-free survival (DFS) is currently ongoing [53]. 
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Metformin and Breast Cancer: Clinical Evidence from Prospective Randomized Trials 
Two prospective clinical trials have explored the possible anticancer activity of 
metformin in BC patients in the early and in the metastatic setting. In the pre-operative 
setting of early BC, the possible role of metformin was evaluated in a window of 
opportunity (WOP) trial of 2–4 week administration between BC diagnosis and surgery 
has been investigated in many clinical trials [51,54,55]. In all these studies, the possible 
effects of metformin in inhibiting cancer cell proliferation was assessed by analyzing 
tumor proliferation, i.e., Ki 67, gene expression modification or reduction of insulin 
resistance related markers. 
In particular, a randomized, phase II, double-blind, placebo-controlled trial 
conducted at the European Institute of Oncology, Milan, Italy, compared metformin or 
placebo administered for 4 weeks before surgery in women with stage I–II BC, candidate 
to elective surgery [56]. The primary objective was to evaluate the antiproliferative activity 
of metformin in terms of Ki67 modification. Overall, 200 patients were randomized: 
metformin was not associated with a significant reduction in cancer cell proliferation 
overall, however, a significant reduction was observed in insulin resistant women, 
identified by an HOMA Index value ≥ 2.5. 
More recently, the MYME trial, a phase II, open-label, multicenter, randomized 
clinical study, aimed to evaluate the possible anticancer effect of metformin when added 
to first line chemotherapy in Her2 negative advanced BC. This study enrolled Her2 
negative patients with endocrine-resistant disease, without known T2DM; assessment of 
HOMA index was performed in all patients at baseline, before the start of treatment. 
Patients were randomized to receive liposomal doxorubicin plus cyclophosphamide plus 
metformin 1000 mg twice daily, or chemotherapy alone. Chemotherapy was administered 
every 21 days for a maximum of 8 cycles, metformin was administered until disease 
progression. Randomization was stratified by center and HOMA index (<2.5 vs. ≥2.5), 
chosen as the cut-off value for insulin resistance based on the results from an Italian-based 
population study [57]. One hundred twenty-six patients have been enrolled. This was an 
interesting study, as it paid attention to anthropometric evaluations, including BMI 
calculation and the waist to hip ratio (WHR); in parallel, it performed host metabolism 
serum analyses such as glycaemia, lipidaemia, serum free fatty acid levels, triglycerides, 
total cholesterol, high and low density lipoprotein, hormones (insulin, C-peptide, 
norepinephrine, cortisol), and inflammatory markers. This is the first study to evaluate 
the impact of the addition of metformin to first-line chemotherapy in BC: no advantage in 
progression free survival (PFS) and OS was, however, observed in the combination 
regimen. Unexpectedly, no benefit in PFS was observed in insulin-resistant patients. This 
was surprising, since previous data demonstrated a significant interaction between 
metformin and HOMA index, especially in luminal B tumors, supporting the hypothesis 
of an indirect effect of metformin in insulin-resistant patients [51]. The MYME study does 
not confirm this hypothesis, suggesting that the potential anti-cancer effect of metformin 
on host metabolism could be less important in modulating response to chemotherapy. Of 
note, this study demonstrated a possible independent prognostic role of insulin, as 
insulin-resistant patients showed a significantly lower PFS compared to non-insulin-
resistant women, irrespective of the use of metformin. Furthermore, in this analysis, no 
detrimental role of BMI and obesity was observed. From all these findings, we are able to 
conclude that obesity, per se, is not an independent prognostic factor in BC, whereas 
plasma insulin levels and insulin resistance seem to be related to BC prognosis. 
Interestingly, metformin demonstrated to be able to restore insulin sensibility in a 
subgroup of patients with basal HOMA index >2.5, without a beneficial effect in PFS and 
OS. 
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5. Translational Insights 
The prognostic role of the insulin/IGF pathway has also been investigated on 
circulating tumor cells (CTCs) in BC patients. The analysis of the IGF-1R expression on 
CTCs of metastatic patients was first performed by de Bono et al. [58]; in their experience, 
they were able to detect IGF-1R expression by immunofluorescence on CTCs. Moreover, 
patients with high CTCs levels at baseline had high IGF-1R-positive CTCs and a more 
rapid disease progression. Due to the low number of CTCs the technique has been further 
improved to minimize cell loss during the labeling and analysis process by Pizon et al., 
who developed a maintrac® method to avoid cell loss, omitting all enrichment steps 
during the preparation [59]. With this approach, they reported that 84% of BC patients 
harbored IGF-1R positive CTCs with a concordance between IGF-IR expression and CTCs 
count. Conversely, Spiliotaki et al. reported a higher expression of IGF-1R is on CTCs in 
patients with early BC versus metastatic disease with a progressive reduction during the 
transition from early to metastatic stage [60]. Overall, in this study, IGF-1R expression was 
detected in 79% of CTC-positive metastatic patients. Moreover, higher levels of IGF-1R 
positive CTCs before starting adjuvant chemotherapy were correlated with an improved 
prognosis in terms of DFS and OS. Recently, the TransMyme project has evaluated the 
prognostic role of IGF-1R expression on CTCs collected in 72 patients enrolled in the 
MYME study [56]. Interestingly, an increased risk of disease progression or death was 
observed in patients with ≥4 IGF-1R negative CTCs; this was the largest prospective 
observation so far, evaluating the prognostic role of IGF1-R expression on CTCs in BC 
patients and these results support further evaluation of the role of IGF-1R on CTCs to 
improve patient stratification and to implement new targeted strategies. 
Another emerging issue is the cross-talk between cancer metabolism and host related 
immune status, due to the relationship between metabolic impairment and chronic 
inflammation. In particular, current research is focused on the evaluation of aberrant 
myelopoiesis, leading to an immunosuppressive environment, possibly due to the 
accumulation of myeloid-derived suppressor cells (MDSCs) that suppress adaptive 
immunity favoring cancer cell proliferation [31,61]. 
6. Conclusions 
A growing body of evidence indicates a strong association between host metabolism 
and cancer. Hyperinsulinemia and obesity play important and independent roles and 
have been consistently associated with an adverse prognosis in many types of cancers, 
including BC. A possible correlation between BMI, hyperinsulinemia, metabolic 
dysfunction, increase of circulating inflammatory cytokines and BC risk has been reported 
in retrospective and prospective evidences. Metformin has been shown to interfere with 
carcinogenesis through direct and indirect mechanisms, supporting the hypothesis of its 
possible role in preventing biologically aggressive BC; however, its possible role as an 
anticancer agent in BC is still controversial and evidence from randomized prospective 
studies is lacking. The possible interplay between metabolism and the immune system in 
cancer patients is currently considered an emerging research field. In conclusion, obesity, 
metabolic syndrome, and insulin resistance are all involved in BC risk and prognosis; this 
effect is possibly mediated by a pro-inflammatory state, mediated by cytokines 
originating in fat tissue. 
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